Analysis of ventricular arrhythmias and sudden death from prospective, randomized clinical trials of acalabrutinib

Summary This analysis investigated the incidence of sudden deaths (SDs) and non‐fatal and fatal ventricular arrhythmias (VAs) in five acalabrutinib clinical trials. In total, 1299 patients received acalabrutinib (exposure, 4568.4 patient‐years). Sixteen (1.2%) patients experienced SD or VA (event rate, 0.350/100 patient‐years). Non‐fatal VAs occurred in 11 (0.8%) patients, nine (0.7%) of whom had premature ventricular contractions only. SD and fatal VAs occurred in five (0.4%) patients (event rate, 0.109/100 patient‐years; median time to event: 46.2 months). SDs and VAs with acalabrutinib occurred at low rates, and there are insufficient data to point to an increased risk of SD or VA with acalabrutinib.